Cat. No. 5582
Biological ActivitySelective HIF-1 dimerization inhibitor. Blocks protein-protein interaction of recombinant HIF-1α, but not HIF-2α, with HIF-1β (IC50 = 1.3 μM) . Inhibits hypoxia-induced HIF-1 activity, and decreases VEGF and CAIX expression in osteosarcoma and breast cancer cells in vitro. Also reduces tubularization of hypoxic HUVECs.
(Modifications: Lactam bridge: Cys-1 to Tyr-6), Disulfide bridge: 1-1*)
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Data Sheet
Miranda et al (2013) A cyclic peptide inhibitor of HIF-1 heterodimerization that inhibits hypoxia signaling in cancer cells. J.Am.Chem.Soc. 135 10418. PMID: 23796364.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses TAT-cyclo-CLLFVY from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: TAT-cyclo-CLLFVY, supplier, HIF-1a, 1b, 1beta, 1alpha, α, β, hypoxia, inducible, factor, cancer, angiogenesis, antiangiogenic, dimerization, inhibitors, inhibits, Tocris Bioscience, Hypoxia Inducible Factor Inhibitor products
Find multiple products by catalog number
New Products in this Area
Gene switch ligand for use in induceable gene expression systems
Follow Tocris on LinkedIn
Visit our LinkedIn page for the latest Tocris news, events and updates.